Alveus Therapeutics closed a $160 million financing to advance its lead obesity program into Phase 2. The company’s primary candidate targets the same receptor combination as Amgen’s MariTide but is positioned for a different dosing or delivery profile, and Alveus also disclosed work on complementary amylin‑targeting approaches. Investors backed the clinical push as the obesity drug category continues to attract outsized interest; Alveus said the capital will support Phase 2 studies and broaden its pipeline toward market differentiation against several high‑profile competitors.